Search results for "Fen"

showing 10 items of 3710 documents

Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain

2017

AbstractMutations in the GDAP1 gene can cause Charcot-Marie-Tooth disease. These mutations are quite rare in most Western countries but not so in certain regions of Spain or other Mediterranean countries. This cross-sectional retrospective multicenter study analyzed the clinical and genetic characteristics of patients with GDAP1 mutations across Spain. 99 patients were identified, which were distributed across most of Spain, but especially in the Northwest and Mediterranean regions. The most common genotypes were p.R120W (in 81% of patients with autosomal dominant inheritance) and p.Q163X (in 73% of autosomal recessive patients). Patients with recessively inherited mutations had a more seve…

0301 basic medicineMaleCross-sectional studyDiseasemedicine.disease_causeCorrelation0302 clinical medicineCharcot-Marie-Tooth DiseaseGenotypePathologyYoung adultGeography MedicalChildGeneticsMutationMultidisciplinaryQRMiddle AgedPatologiaFenotipPhenotypeChild PreschoolMedicineFemalemedicine.symptomAdultAdolescentScienceNerve Tissue ProteinsAmiotròfia neural progressiva de Charcot-Marie-ToothCharcot-Marie-Tooth diseaseAsymptomaticArticle03 medical and health sciencesYoung AdultMagnetic resonance imagingImatges per ressonància magnèticamedicineHumansEspanyaGenetic Association StudiesAgedRetrospective Studiesbusiness.industryMutació (Biologia)Retrospective cohort studyMutation (Biology)030104 developmental biologyCross-Sectional StudiesSpainMutationbusiness030217 neurology & neurosurgery
researchProduct

Exposure to Bisphenol A and Phthalates during Pregnancy and Ultrasound Measures of Fetal Growth in the INMA-Sabadell Cohort

2016

Background: Prenatal exposure to bisphenol A (BPA) and phthalates may affect fetal growth; however, previous findings are inconsistent and based on few studies. Objectives: We assessed whether prenatal exposure to BPA and phthalates was associated with fetal growth in a Spanish birth cohort of 488 mother–child pairs. Methods: We measured BPA and eight phthalates [four di(2-ethylhexyl) phthalate metabolites (DEHPm), mono-benzyl phthalate (MBzP), and three low-molecular-weight phthalate metabolites (LMWPm)] in two spot-urine samples collected during the first and third trimester of pregnancy. We estimated growth curves for femur length (FL), head circumference (HC), abdominal circumference (A…

0301 basic medicineMaleHealth Toxicology and MutagenesisEmbaràsFetal growth010501 environmental sciences01 natural sciencesCohort StudiesFetal DevelopmentBisphenol APhthalatesPregnancyPrenatal exposureFetal growthBirth WeightMaternal-Fetal ExchangeMaternal-fetal exchangePhenols toxicityObstetricsÀcid ftàlicEnvironmental exposureMaternal ExposureCohortChildren's HealthINMA study/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingChristian ministryFemaleUltrasonographyAdultmedicine.medical_specialtyAdolescentPhthalic AcidsUltrasonography Prenatal03 medical and health sciencesBisfenol A -- Toxicologia -- EpidemiologiaPhenolsSDG 3 - Good Health and Well-beingmedicineHumansBenzhydryl Compounds0105 earth and related environmental sciencesPregnancybusiness.industryPublic Health Environmental and Occupational HealthInfant NewbornSabadell (Barcelona Spain)Environmental Exposuremedicine.disease030104 developmental biologySpainbusiness
researchProduct

Preventive Effect of Cow's Milk Fermented with Lactobacillus paracasei CBA L74 on Common Infectious Diseases in Children: A Multicenter Randomized Co…

2017

Background: Fermented foods have been proposed to prevent common infectious diseases (CIDs) in children attending day care or preschool. Objectives: To investigate the efficacy of dietary supplementation with cow’s skim milk fermented with the probiotic Lactobacillus paracasei CBA L74 in reducing CIDs in children attending day care or preschool. Methods: Multicenter, randomized, double-blind, placebo-controlled trial on healthy children (aged 12–48 months) consuming daily 7 grams of cow’s skim milk fermented with L. paracasei CBA L74 (group A), or placebo (maltodextrins group B) attending day care or preschool during the winter season. The main outcome was the proportion of children who exp…

0301 basic medicineMalePediatricsCultured Milk ProductsGroup Blaw.inventionDefensinsFeces0302 clinical medicineRandomized controlled triallawOtitisacute gastroenteritisinnate immunityRhinitisNutrition and DieteticsbiologyAbsolute risk reductionfood and beveragesPharyngitisLacticaseibacillus paracaseiGastroenteritisMilkChild Preschool030211 gastroenterology & hepatologyFemaleTracheitisprobioticacute gastroenteritimedicine.medical_specialtyLactobacillus paracaseiPlaceboCommunicable DiseasesArticle03 medical and health sciencesDouble-Blind MethodCathelicidinsInternal medicinemedicineAnimalsHumansimmunonutritionFecesIntention-to-treat analysisgut microbiotabusiness.industryProbioticsInfantacute gastroenteritis; upper respiratory tract infections; probiotics; innate immunity; acquired immunity; gut microbiota; immunonutritionupper respiratory tract infectionsbiology.organism_classificationmedicine.diseaseImmunoglobulin Aacquired immunity030104 developmental biologyUpper respiratory tract infectionupper respiratory tract infectionSample SizeFermentationCattlebusinessFood ScienceAntimicrobial Cationic Peptides
researchProduct

Polyphenol Levels Are Inversely Correlated with Body Weight and Obesity in an Elderly Population after 5 Years of Follow Up (The Randomised PREDIMED …

2017

Overweight and obesity have been steadily increasing in recent years and currently represent a serious threat to public health. Few human studies have investigated the relationship between polyphenol intake and body weight. Our aim was to assess the relationship between urinary polyphenol levels and body weight. A cross-sectional study was performed with 573 participants from the PREDIMED (Prevención con Dieta Mediterránea) trial (ISRCTN35739639). Total polyphenol levels were measured by a reliable biomarker, total urinary polyphenol excretion (TPE), determined by the Folin-Ciocalteu method in urine samples. Participants were categorized into five groups according to their TPE at the fifth …

0301 basic medicineMaleobesityCross-sectional studyUrineOverweightBody Mass IndexSurveys and QuestionnairesPrevalenceCiències de la salutWaist-to-height ratioNutrition and DieteticsConfoundingMiddle AgedCiencias de la saludurinePolifenolsObesitatFemalemedicine.symptomWaist CircumferencePREDIMEDmedicine.medical_specialtyWaistArticle03 medical and health sciencesInternal medicinemedicineHumansoverweightObesityAged030109 nutrition & dieteticsWaist-Height Ratiobusiness.industryBody WeightHealth sciencesPolyphenolsNUTRICIÓoverweight; obesity; polyphenol; urine; PREDIMEDDIETOTERÀPIA2072-6643medicine.diseaseObesitySurgerypolyphenolCross-Sectional StudiesNutrition AssessmentbusinessBody mass indexBiomarkersFood ScienceFollow-Up StudiesNutrients
researchProduct

Identification of New Antimicrobial Peptides from Mediterranean Medical Plant Charybdis pancration (Steinh.) Speta

2020

The present work was designed to identify and characterize novel antimicrobial peptides (AMPs) from Charybdis pancration (Steinh.) Speta, previously named Urginea maritima, is a Mediterranean plant, well-known for its biological properties in traditional medicine. Polypeptide-enriched extracts from different parts of the plant (roots, leaves and bulb), never studied before, were tested against two relevant pathogens, Staphylococcus aureus and Pseudomonas aeruginosa. With the aim of identifying novel natural AMPs, peptide fraction displaying antimicrobial activity (the bulb) that showed minimum inhibitory concentration (MICs) equal to 30 &micro

0301 basic medicineMicrobiology (medical)Charybdis030106 microbiologyAntimicrobial peptides) SpetaSettore BIO/05 - ZoologiatemporinPeptidemedicine.disease_causeSettore BIO/19 - Microbiologia GeneraleBiochemistryMicrobiologyMicrobiologyantibiotic resistant strains03 medical and health sciencesMinimum inhibitory concentrationAntibiotic resistancemedicinePharmacology (medical)high-resolution mass spectrometryGeneral Pharmacology Toxicology and Pharmaceuticsplant defensinschemistry.chemical_classificationbiologyPseudomonas aeruginosaantimicrobial peptides from plantCharybdis pancration (Steinh.) SpetaSettore BIO/02 - Botanica Sistematicalcsh:RM1-950temporinsbiology.organism_classificationAntimicrobialplant defensinmolecular dynamicslcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseaseschemistryStaphylococcus aureusCharybdis pancration (Steinhantimicrobial peptides from plants<i>Charybdis pancration</i> (Steinh.) Spetaantibiotic resistant strainAntibiotics
researchProduct

Microbial communities of lycaenid butterflies do not correlate with larval diet

2016

Herbivores possess many counteradaptations to plant defenses, and a growing body of research describes the role of symbiotic gut bacteria in mediating herbivorous diets among insects. However, persistent bacterial symbioses have not been found in Lepidoptera, despite the fact that perhaps 99% of the species in this order are herbivorous. We surveyed bacterial communities in the guts of larvae from 31 species of lycaenid butterflies whose caterpillars had diets ranging from obligate carnivory to strict herbivory. Contrary to our expectations, we found that the bacterial communities of carnivorous and herbivorous caterpillars do not differ in richness, diversity, or composition. Many of the o…

0301 basic medicineMicrobiology (medical)lcsh:QR1-502gut microbiomeAphytophagyMicrobiologylcsh:MicrobiologyLepidoptera genitalia03 medical and health sciencesSymbiosisPlant defense against herbivoryhorizontal gene transfer (HGT)HerbivoryOriginal ResearchHerbivoreLarvaObligatebiologyEcologyfungiLycaenidaebiology.organism_classificationLepidoptera030104 developmental biologyLycaenidaehorizontal gene transferSpecies richnessFrontiers in Microbiology
researchProduct

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

2019

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 2–4 years after diagnosis. A significant number of IPF patients have risk factors, such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer (LC) (mostly non-small cell lung cancer (NSCLC)). In fact, IPF itself increases the risk of LC development by 7% to 20%. In this regard, there are multiple common genetic, molecular, and cellular processes that connect lung fibrosis with LC, such as myofibroblast/mesenchymal transition, myofibroblast activation and uncontrolled proliferation, endoplasmic reticulum stress, alterat…

0301 basic medicineOncologyIndolesLung Neoplasmsnon-small cell lung cancer (NSCLC)Reviewlcsh:Chemistrychemistry.chemical_compoundIdiopathic pulmonary fibrosis0302 clinical medicineCarcinoma Non-Small-Cell LungMyofibroblastslcsh:QH301-705.5SpectroscopyGeneral MedicinePirfenidonerespiratory systemComputer Science Applicationsnon-small cell lung cancer (NSCLC)030220 oncology & carcinogenesisNintedanibidiopathic pulmonary fibrosis (IPF)Myofibroblastmedicine.drugmedicine.medical_specialtyPyridonesAntineoplastic AgentsCatalysisInorganic Chemistry03 medical and health sciencesInternal medicinemedicineAnimalsHumansPhysical and Theoretical ChemistryLung cancerMolecular Biologylung cancer (LC)business.industryOrganic ChemistryMesenchymal stem cellmedicine.diseaseIdiopathic Pulmonary Fibrosisrespiratory tract diseases030104 developmental biologylcsh:Biology (General)lcsh:QD1-999chemistryConcomitantbusinessInternational Journal of Molecular Sciences
researchProduct

Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer.

2017

&lt;b&gt;&lt;i&gt;Background/Aim:&lt;/i&gt;&lt;/b&gt; A clinical trial demonstrated that treatment with oral multikinase regorafenib improved overall survival (OS), progression-free survival (PFS), and disease control [García-Alfonso et al.: J Clin Transl Oncol 2016;18:1072-1081; Bertocchi et al.: J Chemother 2017;29:102-105]. In this study, we aimed to evaluate its effectiveness in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy with docetaxel plus prednisone. &lt;b&gt;&lt;i&gt;Materials and Methods:&lt;/i&gt;&lt;/b&gt; 60 patients were enrolled. OS has been assessed as the primary endpoint while PFS, quality o…

0301 basic medicineOncologyMaleCancer ResearchColorectal cancerPyridinesmedicine.medical_treatmentDocetaxelKaplan-Meier Estimatechemistry.chemical_compound0302 clinical medicineQuality of lifeAntineoplastic Combined Chemotherapy ProtocolsMedicineRegorafenibAged 80 and overMetastatic colorectal cancerGeneral MedicineMiddle AgedProstatic Neoplasms Castration-ResistantTreatment OutcomeOncology030220 oncology & carcinogenesisAdenocarcinomaFemaleTaxoidsColorectal NeoplasmsAdultmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaDisease-Free Survival03 medical and health sciencesRegorafenibInternal medicineOverall survivalChemotherapyHumansAgedRetrospective StudiesChemotherapybusiness.industryPhenylurea Compoundsmedicine.diseaseClinical trial030104 developmental biologychemistryQuality of LifePrednisonebusinessOncology
researchProduct

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

2018

Background: Concomitant radiation with BRAF inhibitor (BRAFi) therapy may increase radiation-induced side effects but also potentially improve tumour control in melanoma patients. Methods: A total of 155 patients with BRAF-mutated melanoma from 17 European skin cancer centres were retrospectively analysed. Out of these, 87 patients received concomitant radiotherapy and BRAFi (59 vemurafenib, 28 dabrafenib), while in 68 patients BRAFi therapy was interrupted during radiation (51 vemurafenib, 17 dabrafenib). Overall survival was calculated from the first radiation (OSRT) and from start of BRAFi therapy (OSBRAFi). Results: The median duration of BRAFi treatment interruption prior to radiothera…

0301 basic medicineOncologyMaleCancer ResearchRadiation-Sensitizing AgentsSkin Neoplasmsmedicine.medical_treatmentMedizinCohort Studies0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsOximesVemurafenibProspective cohort studyMelanomaAged 80 and overMelanomaImidazolesMiddle AgedTreatment OutcomeOncology030220 oncology & carcinogenesisFemalemedicine.drugAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyAdolescentDrug Administration ScheduleBRAF03 medical and health sciencesYoung AdultInternal medicinemedicineHumansddc:610dabrafenibProtein Kinase InhibitorsradiotherapyAgedRetrospective Studiesbusiness.industryDabrafenibRetrospective cohort studymedicine.diseaseRadiation therapyradiation030104 developmental biologyVemurafenibConcomitantClinical StudySkin cancerbusinessBritish Journal of Cancer
researchProduct

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma

2017

Despite markedly improved treatment options for metastatic melanoma, resistance to targeted therapies such as BRAF inhibitors (BRAFi) or BRAFi plus MEK inhibitors (MEKi) remains a major problem. Our aim was to characterize progression on BRAFi therapy and outcome of subsequent treatment. One hundred and eighty patients with BRAF-mutant metastatic melanoma who had progressed on treatment with single-agent BRAFi from February 2010 to April 2015 were included in a retrospective data analysis focused on patterns of progression, treatment beyond progression (TBP) and subsequent treatments after BRAFi therapy. Analysis revealed that 51.1% of patients progressed with both new and existing metastas…

0301 basic medicineOncologyMaleCancer ResearchSkin NeoplasmsBRAF inhibitorProgrammed Cell Death 1 ReceptorMedizinKaplan-Meier Estimate0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsVemurafenibMelanomaOriginal ResearchAged 80 and overTreatment optionsMiddle AgedMAP Kinase Kinase KinasesPrognosisProgression-Free SurvivalOncology030220 oncology & carcinogenesisDisease ProgressionvemurafenibFemalemedicine.drugmetastatic melanomaBRAF inhibitorAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyMetastatic melanomaRetrospective data03 medical and health sciencesYoung AdultInternal medicinetreatment beyond progressionmedicineOverall survivalHumansRadiology Nuclear Medicine and imagingIn patientdabrafenibProtein Kinase InhibitorsResponse Evaluation Criteria in Solid TumorsAgedRetrospective Studiesbusiness.industryClinical Cancer ResearchDabrafenib030104 developmental biologyBRAF mutationDrug Resistance NeoplasmMutationprogressionbusinessFollow-Up StudiesCancer Medicine
researchProduct